May 14, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that ...

Acumen Pharmaceuticals (ABOS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Thomas Shrader from BTIG maintained a Buy rating on the stock and ...

Acumen Pharmaceuticals has dosed the first patient in ALTITUDE-AD, a Phase II trial designed to evaluate the clinical ...

Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting ...

Acumen Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.00025, expectations were $-0.23. Operator: Good ...

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AßOs) for the treatment of Alzheimer’s ...

Tactician par excellence Gautam Gambhir couldn't have envisaged a battle of brains with a more different kind of adversary ...

Good day and thank you for standing by. Welcome to Acumen Pharmaceuticals First Quarter 2024 Conference Call and Webcast. [Operator Instructions] Please be advised that today's conference is being ...

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted ...

The results build upon Acumen’s prior presentations at the AD/PD™ 2024 Annual Meeting and positive topline data first announced in July 2023, highlighting sabirnetug as the first humanized monoclonal ...